IL6 and systemic sclerosis: Collectively, these findings indicate that, in SSc, although IL-6 may contribute to fibrosis (Fig. 2) (Denton et al. 2018), elevated IL-6 expression in the oral cavity may simply reflect the early phase of SSc or that SSc patients show a hyperactive immune response and thus may not be a direct contributor to oral disease progression.